Table 2 Comparison of CYP2C9*1 and CYP2C9*3 among study groups
Patients with drug-related ADRs (both idiosyncratic and dose-related) | |||
|---|---|---|---|
Genotypes | Phenytoin-induced ADRs (n = 142) (Group 1) Number of patients (%age) | No ADR (Group 2) (n = 100) Number of patients (%age) | p value |
CYP2C9*1/*1 | 92 (64.78%) | 85 (85%) | 3*/1* versus 1*/1* p = 0.005 3*/3* versus 1*/1* p = 0.004 |
CYP2C9*1/*3 | 41 (28.87%) | 15 (15%) | |
CYP2C9*3/*3 | 9 (6.3%) | 2 | |
Patients with drug-related ADRs (both idiosyncratic and dose-related) | |||
|---|---|---|---|
Genotypes | Phenytoin-induced idiosyncratic (dose-independent) ADRs (n = 95) Number of patients (%age) | No ADR (Group 2) (n = 100) Number of patients (%age) | p |
CYP2C9*1/*1 | 64 (67.36%) | 85 (85%) | 3*/1* versus 1*/1* p = 0.06 3*/3* versus 1*/1* p = 0.001 3*/3* + 3*/ 1* versus 1*/1*; p = 0.004 |
CYP2C9*1/*3 | 23 (24.21%) | 15 (15%) | |
CYP2C9*3/*3 | 8 (8.42%) | 0 (0%) | |
Patients with drug-related ADRs (both idiosyncratic and dose-related) | |||
|---|---|---|---|
|  | Phenytoin-induced dose-related ADRs (n = 66) Number of patients (%age) | No ADR (n = 100) (Group 2) Number of patients (%age) | p |
CYP2C9*1/*1 | 39 (59.09%) | 85 (85%) | 3*/1* versus 1*/1* p = 0.005 3*/3* versus 1*/1* p = 0.03 3*/3* + 3*/ 1* versus 1*/1*; p < 0.001 |
CYP2C9*1/*3 | 23 (34.84%) | 15 (15%) | |
CYP2C9*3/*3 | 4 (6.06%) | 0 (0%) | |
Patients with drug-related ADRs (both idiosyncratic and dose-related) | |||
|---|---|---|---|
|  | Phenytoin-induced skin rash (n = 49) Number of patients (%age) | No ADR (n = 100) (Group 2) Number of patients (%age) | p |
CYP2C9*1/*1 | 32 (65.30%) | 85 (85%) | 3*/1* versus 1*/1* p = 0.15 3*/3* versus 1*/1* p = 0.0006 3*/3* + 3*/ 1* versus 1*/1*; p = 0.007 |
CYP2C9*1/*3 | 11 (22.44%) | 15 (15%) | |
CYP2C9*3/*3 | 6 (12.24%) | 0 (0%) | |
Patients with drug-related ADRs (both idiosyncratic and dose-related) | |||
|---|---|---|---|
|  | Phenytoin-induced gum hyperplasia (n = 51) Number of patients (%age) | No ADR (Group 2) (n = 100) Number of patients (%age) | p |
CYP2C9*1/*1 | 32 (65.30%) | 85 (85%) | 3*/1* versus 1*/1* p = 0.14 3*/3* versus 1*/1* p = 0.02 3*/3* + 3*/ 1* versus 1*/1*; p = 0.04 |
CYP2C9*1/*3 | 11 (22.44%) | 15 (15%) | |
CYP2C9*3/*3 | 6 (12.24%) | 0 (0%) | |